What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is a partial sequence derived from human gastric juice protein BPC. Unlike the incretin-axis compounds, BPC-157 does not act on G protein-coupled receptors associated with metabolic signalling; instead, its research profile centres on tissue biology, extracellular matrix interactions, and inflammatory pathway modulation.
BPC-157 is studied in vitro in fibroblast cultures, endothelial cell preparations, and smooth muscle cell models.
Research Profile of BPC-157
Laboratory investigation of BPC-157 examines its effects across multiple cellular systems:
- Collagen synthesis and fibroblast behaviour in extracellular matrix models
- Angiogenesis-related signalling, including interactions with vascular endothelial growth factor (VEGF) pathways
- Inflammatory mediator modulation in cytokine assay models
- Cellular stress response and survival signalling in oxidative challenge assays
BPC-157 does not have an established single receptor target, making its mechanism of action an active area of in vitro research. This mechanistic uncertainty makes BPC-157 a compound of particular interest for exploratory pathway mapping studies.
The KLOW Compound
KLOW is a multi-peptide research compound combining four distinct compounds into a single lyophilised preparation. Each component brings a distinct research profile:
Synthetic pentadecapeptide studied for tissue biology and extracellular matrix interactions. The primary compound in the KLOW formulation.
An actin-sequestering peptide studied for its role in cytoskeletal regulation, cell migration, and wound-related cellular signalling pathways.
A naturally occurring plasma tripeptide studied for collagen synthesis, metalloproteinase regulation, and antioxidant pathway interactions in cell models.
A tripeptide derived from the C-terminus of alpha-MSH, studied for its role in inflammatory signalling modulation, particularly in NF-κB pathway research.
Why Multi-Peptide Research?
Combining these four compounds allows researchers to examine potential synergistic interactions in tissue biology models that would not be detectable when studying each peptide in isolation. The combined profile of BPC-157, TB-500, GHK-Cu, and KPV spans extracellular matrix biology, cytoskeletal regulation, redox signalling, and inflammatory pathway modulation.
KLOW is particularly relevant to research programmes examining collagen matrix remodelling, inflammatory resolution, and cellular resilience under stress conditions. The single-vial format simplifies preparation for studies requiring all four compounds concurrently.
Available from Nova Biolabs
KLOW is supplied as a single lyophilised vial at £60, held in UK domestic stock. For laboratory research use only.